Biogen: raises its adjusted EPS guidance for 2024

(CercleFinance.com) - Biogen reports Q3 sales of $2,466 million, down 3% on the same period a year earlier.


The company reported net income, group share of $388 million, a far cry from the $68 million loss recorded a year earlier, giving EPS of $2.67, compared with -$0.47 in Q3 2023.

On an adjusted basis, EPS came to $4.08, down 6%.

'We continue to see momentum with new product launches, and are increasingly enthusiastic about the potential of our pipeline. This quarter we have seen several significant positive developments in key areas of our late-stage pipeline, which we believe underscores the potential value for both patients and shareholders", says Christopher A. Viehbacher, CEO of Biogen.

In this context, Biogen is raising its adjusted EPS guidance for 2024, now targeting a range of $16.1 to $16.6, vs. $15.75 to $16.25 previously.

Copyright (c) 2024 CercleFinance.com. All rights reserved.